Skip to main content

BioMicro Systems Closes Series B Funding, Plans to Broaden Product Line

NEW YORK (GenomeWeb News) - BioMicro Systems said today it has closed a round of Series B financing with investors vSpring, Nanostart, and Staley Capital Advisors.
 
BioMicro, which markets the MAUI hybridization product line, did not disclose the amount of funding it received in this round, but said the new investments bring the total it has raised since inception to $10 million.
 
Company CEO Michael Feldman said BioMicro plans to use the money to "broaden our product portfolio to include Kreatech reagents, Arrayjet microarrayers and soon-to-be-announced new products."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.